Expert review of respiratory medicine最新文献_第2页

Hospital discharge protocol for patients with chronic obstructive pulmonary disease: expert consensus from India. 慢性阻塞性肺疾病患者的出院协议：来自印度的专家共识。

Expert review of respiratory medicine Pub Date : 2025-07-15 DOI: 10.1080/17476348.2025.2527963

Harjit Dumra, Sanjay Mittal, Devasahayam J Christopher, Sushmita Roy Chowdhury, Lancelot Pinto, P Arjun, Arjun Khanna

{"title":"Hospital discharge protocol for patients with chronic obstructive pulmonary disease: expert consensus from India.","authors":"Harjit Dumra, Sanjay Mittal, Devasahayam J Christopher, Sushmita Roy Chowdhury, Lancelot Pinto, P Arjun, Arjun Khanna","doi":"10.1080/17476348.2025.2527963","DOIUrl":"10.1080/17476348.2025.2527963","url":null,"abstract":"Introduction: Chronic obstructive pulmonary disorder (COPD) is a significant health challenge in India, mainly attributed to smoking, air pollution, and biomass fuel exposure. Severe COPD is associated with frequent hospitalization due to recurring exacerbations, leading to increased healthcare utilization and economic burden, and a higher risk of cardiovascular events and mortality. Preventing exacerbations is key to slowing disease progression, as each exacerbation worsens lung function and increases the risk of future exacerbations. Evidence suggests that implementing evidence-based discharge care bundles may reduce hospital readmissions and improve patient outcomes. A virtual advisory board meeting involving 7 leading experts from pulmonary medicine and cardiology specialties was convened in June 2024 to gain insights into the current unmet needs in managing COPD exacerbations, particularly focused on discharge protocols.Areas covered: Targeted, nonsystematic literature searches using MEDLINE databases focused on local or national discharge protocols/guidelines for COPD patients' post-exacerbation, their clinical implementation, and identified challenges and gaps encountered following hospital discharge.Expert opinion: The panel proposed a standardized COPD discharge protocol based on local clinical practices for uniform implementation and uptake across all healthcare settings in India. Experts recommended prioritizing the accessible and affordable interventions including smoking cessation, education of patients and caregivers, medication reconciliation, and referral to home-based pulmonary rehabilitation programs.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of COPD exacerbations in hospital emergency departments. 医院急诊科慢性阻塞性肺病加重的管理。

Expert review of respiratory medicine Pub Date : 2025-07-12 DOI: 10.1080/17476348.2025.2530207

Pascual Piñera Salmerón, Esther Pulido Herrero, Raúl Perales Muñoz, Arturo Huerta García, Raúl Alonso Avilés, Cesar Cinesi Gómez, Juan González Del Castillo

{"title":"Management of COPD exacerbations in hospital emergency departments.","authors":"Pascual Piñera Salmerón, Esther Pulido Herrero, Raúl Perales Muñoz, Arturo Huerta García, Raúl Alonso Avilés, Cesar Cinesi Gómez, Juan González Del Castillo","doi":"10.1080/17476348.2025.2530207","DOIUrl":"10.1080/17476348.2025.2530207","url":null,"abstract":"Introduction: Emergency departments (EDs) play a crucial role in managing exacerbation of COPD (ECOPD). However, there is currently no standardization of management criteria for ECOPD within the Spanish healthcare system. This document aims to outline the management of ECOPD in EDs in the context of 2025, serving as a guide for healthcare professionals working in emergency services.Areas covered: Various aspects of the management of ECOPD in EDs are covered in this article, including severity classification, treatments (both pharmacological and nonpharmacological), criteria for hospital admission and discharge from the ED, treatment at discharge, palliative care, and management of frail patients.Expert opinion: The authors, who are members of the Spanish Society of Emergency Medicine (SEMES), emphasize the importance of classifying the severity of the episode and the patient characteristics to tailor care to each individual. The authors also highlight the value of biomarkers, the appropriate use of ventilatory therapies for ECOPD patients, the importance of proper antibiotic management, and the establishment of clear referral protocols to prevent patients from feeling lost in the healthcare system. Finally, the need to personalize post-discharge treatments is underscored to enhance continuity of care and improve health outcomes.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging role of hyperpolarized ¹²⁹Xe MRI in pulmonary hypertension. 超极化129Xe MRI在肺动脉高压中的新作用。

Expert review of respiratory medicine Pub Date : 2025-07-10 DOI: 10.1080/17476348.2025.2529543

Fawaz Alenezi, Anna Costelle, Seth Lee, Bastiaan Driehuys, Sudarshan Rajagopal

引用次数: 0

Addressing advance care planning for idiopathic pulmonary fibrosis: a call to action. 解决特发性肺纤维化的预先护理计划：行动呼吁。

Expert review of respiratory medicine Pub Date : 2025-07-10 DOI: 10.1080/17476348.2025.2528947

Annlise Calypso, Sonye K Danoff, Rebecca Anna Gersten

{"title":"Addressing advance care planning for idiopathic pulmonary fibrosis: a call to action.","authors":"Annlise Calypso, Sonye K Danoff, Rebecca Anna Gersten","doi":"10.1080/17476348.2025.2528947","DOIUrl":"https://doi.org/10.1080/17476348.2025.2528947","url":null,"abstract":"Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by relentless parenchymal scarring, deteriorating pulmonary function, and unpredictable exacerbations. The prognosis remains poor, despite antifibrotic and other therapies. Patients with IPF experience a high symptom burden, frequent hospitalizations, and uncertainty regarding disease progression. Advance care planning (ACP), the process of defining patients' preferences for medical care, is inconsistently implemented in IPF care. This often leads to end-of-life care unaligned with the patient's wishes and increased distress amongst patients and their care partners.Areas covered: In this perspective, we argue for the early and routine integration of ACP into IPF management. We review the multifaceted patient-, provider-, and system-level barriers to ACP and propose actionable strategies to normalize, document, and operationalize patient-centered ACP across the IPF disease trajectory. We highlight the critical need for an interdisciplinary team to best address ACP.Expert opinion: While IPF research has resulted in huge progress in the understanding of disease pathobiology and the expansion of treatment options, perhaps the most patient-centered portion of care remains under-studied. We must prioritize research to better understand an interdisciplinary system of iterative ACP that gives IPF patients a clear voice until the last moment of life.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging immortalized human lung epithelial cell models to study lung cancer: insights from the past and future perspectives. 利用永生化人肺上皮细胞模型研究肺癌：从过去和未来的角度的见解。

Expert review of respiratory medicine Pub Date : 2025-07-09 DOI: 10.1080/17476348.2025.2526777

Mitsuo Sato, Jerry W Shay, John D Minna

引用次数: 0

Research progress in early states of chronic obstructive pulmonary disease: a narrative review on PRISm, pre-COPD, young COPD and mild COPD. 慢性阻塞性肺疾病早期状态的研究进展：PRISm、前期COPD、青年COPD和轻度COPD的叙述性综述

Expert review of respiratory medicine Pub Date : 2025-07-09 DOI: 10.1080/17476348.2025.2526775

Yuepeng Li, Xiaolong Tang, Rui Zhang, Yi Lei, Denian Wang, Zhoufeng Wang, Weimin Li

引用次数: 0

A clinicians' guide to non-invasive ventilation for exacerbated chronic obstructive pulmonary disease. 加重慢性阻塞性肺疾病无创通气临床医生指南

Expert review of respiratory medicine Pub Date : 2025-07-09 DOI: 10.1080/17476348.2025.2529540

Giulia Panzuti, Gilda Giancotti, Stefano Nava, Maria Laura Vega Pittao

{"title":"A clinicians' guide to non-invasive ventilation for exacerbated chronic obstructive pulmonary disease.","authors":"Giulia Panzuti, Gilda Giancotti, Stefano Nava, Maria Laura Vega Pittao","doi":"10.1080/17476348.2025.2529540","DOIUrl":"10.1080/17476348.2025.2529540","url":null,"abstract":"Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a debilitating condition marked by persistent airflow limitation, leading to increased morbidity and mortality. Acute exacerbations of COPD (AECOPD) can cause rapid deterioration, resulting in hypercapnic respiratory failure and respiratory acidosis. Non-invasive ventilation (NIV) is a key treatment for AECOPD, improving gas exchange, oxygenation, and reducing work of breathing while avoiding the risks of invasive mechanical ventilation (IMV).Areas covered: This review highlights NIV role as a first-line therapy in AECOPD management, discussing its mechanisms, indications, and clinical benefits. Proper patient selection, tailored settings, and careful monitoring are crucial for optimizing outcomes and minimizing complications.Expert opinion: The widespread use of NIV in AECOPD management raises concerns about staff expertise, as success depends on patient selection, ventilator settings, and monitoring. Identifying failure predictors is crucial to prevent delayed intubation and poor outcomes. Research should focus on training, reducing errors, and advancing technology, including Artificial Intelligence-driven automation to improve synchrony. Despite its increased use, especially during COVID-19, progress in staff education and technology remains limited. Enhancing clinician confidence and developing intelligent ventilator algorithms are key, but human expertise remains essential in ensuring effective and life-saving NIV application.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-15"},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment strategies for asthma in women throughout the lifespan - in puberty, pregnancy and menopause. 哮喘在女性整个生命周期的治疗策略-在青春期，怀孕和更年期。

Expert review of respiratory medicine Pub Date : 2025-07-07 DOI: 10.1080/17476348.2025.2530205

Vanessa E Murphy, Joerg Mattes, Esha Joshi

{"title":"Treatment strategies for asthma in women throughout the lifespan - in puberty, pregnancy and menopause.","authors":"Vanessa E Murphy, Joerg Mattes, Esha Joshi","doi":"10.1080/17476348.2025.2530205","DOIUrl":"10.1080/17476348.2025.2530205","url":null,"abstract":"Introduction: Asthma is a common chronic disease which disproportionately affects women. While sex hormones are hypothesized to be involved in changes to asthma during puberty, menstruation, pregnancy and menopause, more research is needed to understand the precise mechanisms involved.Areas covered: This review summarizes the challenges in the treatment of asthma during puberty, pregnancy and menopause. PubMed was searched in the past 10 years for 'puberty/pregnancy/menopause' AND 'asthma.' Non-adherence to asthma treatment is a particular challenge in adolescence and pregnancy. Studies have shown a reduction in the use of inhaled corticosteroids, short acting beta agonists and oral corticosteroids in the first trimester compared to pre-pregnancy. Women perceive a risk of these medications which may contribute to non-adherence during pregnancy. Greater understanding of specific risks of asthma on pregnancy outcomes will assist healthcare professionals in making considered decisions for optimized treatment, including provision of an action plan and correction of inhaler technique. During menopause, new onset asthma can occur, and women with respiratory symptoms should be investigated for an asthma diagnosis so as to receive the required treatment.Expert opinion: A personalized medicine approach which assesses treatable traits and provides holistic care may improve outcomes for women with asthma during puberty, pregnancy and menopause.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of obesity on COPD development: unveiling the hidden risks. 肥胖对慢性阻塞性肺病发展的影响：揭示潜在风险。

Expert review of respiratory medicine Pub Date : 2025-07-06 DOI: 10.1080/17476348.2025.2528945

Ioannis Tomos, Nikolaos Skourlis, Georgia Vourli, Eleni Peppa, Antonia Trichopoulou

{"title":"The impact of obesity on COPD development: unveiling the hidden risks.","authors":"Ioannis Tomos, Nikolaos Skourlis, Georgia Vourli, Eleni Peppa, Antonia Trichopoulou","doi":"10.1080/17476348.2025.2528945","DOIUrl":"10.1080/17476348.2025.2528945","url":null,"abstract":"Background: Obesity represents a frequent comorbidity in chronic obstructive pulmonary disease (COPD); however, its exact role as potential risk factor remains unclear. ur aim is to assess obesity's potential role for COPD development.Research design and methods: The HYDRIA survey has been the first national project on the health of the population in Greece. Data regarding individual characteristics, lifestyle choices, medical history, dietary data and somatometric characteristics were recorded through personal interview in a representative sample of the population.Results: Four thousand eleven men and women aged more than 18 years old were enrolled. COPD is more prevalent in obese people (10.1%; 95% CI: 6.0-14.2%) compared to 5.4%; 95% CI: 4.6-6.2% in non-obese participants. In multivariate analysis, obesity continues to be strongly associated with COPD (OR = 1.76 (95% CI: 1.23-2.53); p = 0.002). Age and smoking are also strong risk factors for COPD. The estimated prevalence of self-reported physician-diagnosed COPD in Greece is 5.9%.Conclusions: Obesity may represent a potential unrevealed risk factor for COPD. Focus on obesity should be included in public health campaigns and preventive programs aiming to decrease the burden of disease and provide the necessary optimal management.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. 索他塞普治疗肺动脉高压的疗效和安全性：随机对照试验的荟萃分析。

Expert review of respiratory medicine Pub Date : 2025-07-06 DOI: 10.1080/17476348.2025.2530201

Mohamad Ershed, Ana Beatriz Nardelli da Silva, Ana Clara Felix de Farias Dos Santos, Danhui Heo, Deivyd Vieira Silva Cavalcante, Jafar Aljazeeri

{"title":"Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials.","authors":"Mohamad Ershed, Ana Beatriz Nardelli da Silva, Ana Clara Felix de Farias Dos Santos, Danhui Heo, Deivyd Vieira Silva Cavalcante, Jafar Aljazeeri","doi":"10.1080/17476348.2025.2530201","DOIUrl":"10.1080/17476348.2025.2530201","url":null,"abstract":"Introduction: To evaluate the efficacy and safety of sotatercept, an activin signaling inhibitor, in pulmonary arterial hypertension (PAH).Methods: We searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) comparing sotatercept versus placebo in PAH. We calculated pooled risk ratios (RR) and mean differences (MD) with their 95% confidence intervals (CI) using a random-effects model. Heterogeneity was assessed with I2 statistics. The GRADE approach was used to assess the certainty of evidence.Results: Three RCTs comprising 601 patients were included. Compared to placebo, sotatercept significantly improved 6-minute walk distance (MD 40.57 m; 95% CI 26.64 to 54.5; p < 0.01), and WHO functional class (RR 2.04; 95% CI 1.53 to 2.7; p < 0.01). Sotatercept reduced pulmonary vascular resistance (MD -233.18 dyn·sec·cm-5; 95% CI -295.84 to -170.52; p < 0.01) and pulmonary artery pressure (MD -14.94 mmHg; 95% CI -19.62 to -10.27; p < 0.01) at study end. No significant differences were observed in all-cause mortality or NT-proBNP levels. Sotatercept was associated with epistaxis, increased hemoglobin, and telangiectasia adverse events.Conclusions: Sotatercept improves exercise capacity, WHO functional class and pulmonary hemodynamics in PAH, with an acceptable safety profile. Long-term studies are needed to confirm sustained benefits.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251032174.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0